Clinical trials: Grade III Obesity
Obesity
Transoral Gastric Volume Reduction as an Intervention for Weight Management
The purpose of this study is to evaluate the safety, technical feasibility, and initial effectiveness (i.e., weight loss primarily measured as percent excess weight loss) of TGVR performed using the Bard RESTORe Suturing System
- Trial name
- TRIM (NCT00679848)
- Testing
- RS2 (RESTORe Suturing System)
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- C. R. Bard
Periodontal Diseases, Obesity, Morbid
Gingival Crevicular Fluid of Adiponectin and Resistin As Predictable Implement in Staging and Grading System of Periodontitis
The goal of this clinical trial is to evaluate the relationship between obesity and gingival crevicular fluid resistin and adiponectin in periodontitis patients as well as assess the effect of non-surgical periodontal therapy on…
- Trial name
- NCT06604013
- Testing
- non-surgical full-mouth periodontal therapy without using adjunct disinfectants, GCF level of adiponectin and resistin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Al-Azhar University
Obesity, Insulin Resistance
Probiotics on Body Composition and Insulin Resistance in Patients With Obesity and Its Association With Gut Microbiota
This study aims to evaluate the modifications in body composition and insulin resistance state in patients with grade II and III obesity included in an interventional lifestyle changes program and treated with probiotics (1 x…
- Conditions
- Obesity, Insulin Resistance, Microbial Colonization
- Trial name
- NCT04086173
- Testing
- Probiotics
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
Endometrial Cancer, Endometrial Cancer Stage I
SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer
SHAPE-ENDO is a single-center, open-label, pilot randomized clinical trial conducted at Hospital Universitari de Bellvitge in Barcelona, Spain.
- Conditions
- Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia
- Trial name
- SHAPE-ENDO (NCT07462663)
- Testing
- GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins
- Volunteers
- 80 people
- Sponsor
- Hospital Universitari de Bellvitge
Grade III Obesity, Type 2 Diabetes Mellitus
Metabolic Changes After Bariatric Surgery
Literature data clearly demonstrate that treatment of obese patients is very expensive, long and achieve weight loss may not be permanent, and regardless of whether the treatment dominated diet therapy, physical activity, or…
- Trial name
- NCT02893891
- Testing
- Laparoscopic sleeve gastrectomy, Laparoscopic gastric plication, Intragastric balloon
- Where
- 2 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Ostrava
Obesity Prevention, Obesity
External Body Weight Effects on Body Weight in Adults With Grade II and III Obesity
Obesity is a growing problem in industrialized societies. This condition is associated with an increase in metabolic and cardiovascular diseases.
- Trial name
- NCT06619028
- Testing
- Weighted vest
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Escoles Universitaries Gimbernat
Insulin Resistance, Obesity
Surgical Removal of Visceral Fat Tissue (Omentectomy) Associated to Bariatric Surgery: Effects on Insulin Sensitivity
The intraabdominal fat is associated with insulin resistance, a condition that is in the basis of diabetes, metabolic syndrome and some cardiovascular diseases.
- Conditions
- Insulin Resistance, Obesity, Metabolic Syndrome X
- Trial name
- NCT00545805
- Testing
- Roux-en-Y Gastric Bypass plus total omentectomy, Roux-en-Y Gastric Bypass
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Campinas, Brazil
Obesity & Overweight
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France.
- Trial name
- SEMAFOLLOW (NCT07423481)
- Testing
- SEMAFOLLOW questionnaire
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Nantes University Hospital